Form 4: iTeos Therapeutics CEO Executes Pre-Planned Stock Option Exercises and Sales, Increases Overall Holdings

iTeos Therapeutics, Inc. CEO Michel Detheux engaged in pre-planned transactions, exercising stock options and selling a portion of the acquired shares for profit, while also increasing his total beneficial ownership in the company.

Summary

• Michel Detheux, Chief Executive Officer of iTeos Therapeutics, Inc. (ITOS), reported multiple transactions involving the company's common stock on June 9 and June 10, 2025.
• All transactions were conducted under a Rule 10b5-1 trading plan adopted on March 5, 2025, indicating pre-scheduled activity.
• On June 9, 2025, Mr. Detheux directly exercised options to acquire 8,400 shares at $4.30 per share and subsequently sold all 8,400 shares at a weighted average price of $10.03, ranging from $10.01 to $10.17.
• Additionally, on June 9, 2025, an entity named MG3A, indirectly controlled by Mr. Detheux, exercised options for 43,882 shares at $4.30 per share and sold all 43,882 shares at a weighted average price of $10.03, ranging from $9.98 to $10.17.
• On June 10, 2025, Mr. Detheux directly exercised options for another 8,400 shares at $4.30 per share and sold all 8,400 shares at a weighted average price of $10.02, ranging from $9.99 to $10.06.
• Also on June 10, 2025, MG3A indirectly exercised options for 43,883 shares at $4.30 per share and sold all 43,883 shares at a weighted average price of $10.02, ranging from $9.99 to $10.06.
• Significantly, on June 10, 2025, Mr. Detheux also directly exercised options for an additional 18,000 shares at $4.30 per share without a subsequent sale, increasing his direct holdings.
• Concurrently, MG3A indirectly exercised options for 94,027 shares at $4.30 per share without a subsequent sale, increasing indirect holdings.
• Following all reported transactions, Mr. Detheux's direct beneficial ownership stands at 153,903 shares, and his indirect beneficial ownership through MG3A is 94,027 shares, totaling 247,930 shares.
• The transactions resulted in a net increase in the total number of shares beneficially owned by Mr. Detheux.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there are significant sales, they are part of a pre-planned 10b5-1 program, which mitigates negative interpretations. Crucially, the CEO also increased his overall beneficial ownership by exercising options and holding a substantial portion of the acquired shares, indicating continued long-term confidence.

Positives

• The CEO's transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing equity and reduces the perception of opportunistic selling.
• The exercise of stock options at $4.30 and subsequent sale at approximately $10.02-$10.03 indicates a significant profit for the CEO on these transactions.
• A substantial number of shares (18,000 directly and 94,027 indirectly via MG3A) were acquired through option exercise on June 10, 2025, and were not immediately sold, indicating continued confidence and increased beneficial ownership in the company.

Negatives

• The sale of a significant number of shares by the CEO, even if pre-planned, could be interpreted by some investors as a signal of reduced personal conviction in the stock's immediate upside potential.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This Form 4 filing reflects routine insider equity management within the biotechnology sector. Such transactions, particularly when executed under a Rule 10b5-1 plan, are common for executives managing their personal portfolios and exercising vested equity compensation. The specific prices of the transactions reflect the market value of iTeos Therapeutics shares at the time of sale.

Related Party Transactions

• Transactions were conducted indirectly through MG3A, a Belgian partnership where the reporting person (Michel Detheux) is the manager and his spouse is the successor manager, qualifying it as a related party.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could lead to short-term market speculation, but the pre-planned nature and increased overall beneficial ownership may reassure investors about long-term commitment.
• Employees: No direct impact mentioned, but executive stock transactions can influence employee perception of company stability and leadership confidence.

Key Dates

Recommendation

Keywords

iTeos Therapeutics, ITOS, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, CEO Transactions, Equity Sales, Beneficial Ownership, Biotechnology